BioNTech AG and Genevant Sciences will together develop five mRNA therapeutic programs for rare diseases with high unmet medical need.
The companies have also agreed a series of exclusive licenses covering the application of Genevant’s delivery technology to five of BioNTech’s oncology programs.
The collaboration will combine Genevant’s lipid nanoparticle (LNP) delivery technology with BioNTech’s mRNA drug discovery platform to develop best-in-class therapeutics.
The companies will pursue the co-development and co-commercialisation of five mRNA programs. Genevant and BioNTech will share all future costs and profits for these programs on a 50/50 basis.
The companies aim to initiate clinical development in 2020.